Nektar Therapeutics Increase (Decrease) in Deferred Revenue
Nektar Therapeutics (NKTR) reported Increase (Decrease) in Deferred Revenue of -$6.25 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-09
- Nektar Therapeutics increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$2.57M.
- Nektar Therapeutics increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$3.68M, a 138.24% decline year-over-year.
- Nektar Therapeutics increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$43.75M.
- Nektar Therapeutics increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $19.36M.
- Nektar Therapeutics increase (decrease) in deferred revenue for fiscal 2017 was -$28.27M.
- Nektar Therapeutics increase (decrease) in deferred revenue for fiscal 2016 was -$17.61M.
- Nektar Therapeutics increase (decrease) in deferred revenue for fiscal 2015 was -$17.53M.
- Nektar Therapeutics increase (decrease) in deferred revenue for fiscal 2014 was -$4.66M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$6.25M 10-Q · filed 2018-08-09 | -$49.99M derived: sum of 3 quarters · filed 2018-08-09 | -$30.63M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | -$3.68M 10-Q · filed 2018-05-10 | -$47.42M derived: sum of 2 quarters · filed 2018-05-10 | -$28.06M derived: sum of 3 quarters · filed 2018-05-10 | -$41.57M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-12-31 | -$43.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$24.38M derived: sum of 2 quarters · filed 2018-03-01 | -$37.89M derived: sum of 3 quarters · filed 2018-08-09 | -$28.27M 10-K · filed 2018-03-01 |
| 2017-09-30 | $19.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $5.86M derived: sum of 2 quarters · filed 2018-08-09 | $15.48M 10-Q · filed 2017-11-08 | $10.53M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-06-30 | -$13.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$3.89M 10-Q · filed 2018-08-09 | -$8.84M derived: sum of 3 quarters · filed 2018-08-09 | -$13.80M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $9.62M 10-Q · filed 2018-05-10 | $4.67M derived: sum of 2 quarters · filed 2018-05-10 | -$292.00K derived: sum of 3 quarters · filed 2018-05-10 | -$969.00K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | -$4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$9.91M derived: sum of 2 quarters · filed 2018-03-01 | -$10.59M derived: sum of 3 quarters · filed 2018-03-01 | -$17.61M 10-K · filed 2018-03-01 |
| 2016-09-30 | -$4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.64M derived: sum of 2 quarters · filed 2017-11-08 | -$12.66M 10-Q · filed 2017-11-08 | -$18.36M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$677.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$7.70M 10-Q · filed 2017-08-09 | -$13.40M derived: sum of 3 quarters · filed 2018-03-01 | -$20.80M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | -$7.03M 10-Q · filed 2017-05-10 | -$12.72M derived: sum of 2 quarters · filed 2018-03-01 | -$20.12M derived: sum of 3 quarters · filed 2018-03-01 | -$26.55M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | -$5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$13.10M derived: sum of 2 quarters · filed 2018-03-01 | -$19.52M derived: sum of 3 quarters · filed 2018-03-01 | -$17.53M 10-K · filed 2018-03-01 |
| 2015-09-30 | -$7.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$13.82M derived: sum of 2 quarters · filed 2016-11-04 | -$11.83M 10-Q · filed 2016-11-04 | -$17.98M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$6.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$4.43M 10-Q · filed 2016-08-04 | -$10.58M derived: sum of 3 quarters · filed 2017-03-01 | -$16.73M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $1.99M 10-Q · filed 2016-05-04 | -$4.15M derived: sum of 2 quarters · filed 2017-03-01 | -$10.31M derived: sum of 3 quarters · filed 2017-03-01 | $3.29M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$12.30M derived: sum of 2 quarters · filed 2017-03-01 | $1.29M derived: sum of 3 quarters · filed 2017-03-01 | -$4.66M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$6.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $7.44M derived: sum of 2 quarters · filed 2015-11-06 | $1.48M 10-Q · filed 2015-11-06 | $4.00M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $13.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $7.64M 10-Q · filed 2015-08-06 | $10.15M derived: sum of 3 quarters · filed 2016-02-29 | -$1.95M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$5.96M 10-Q · filed 2015-05-01 | -$3.44M derived: sum of 2 quarters · filed 2016-02-29 | -$15.54M derived: sum of 3 quarters · filed 2016-02-29 | -$21.07M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$9.58M derived: sum of 2 quarters · filed 2016-02-29 | -$15.11M derived: sum of 3 quarters · filed 2016-02-29 | -$12.40M 10-K · filed 2016-02-29 |
| 2013-09-30 | -$12.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$17.62M derived: sum of 2 quarters · filed 2014-11-07 | -$14.91M 10-Q · filed 2014-11-07 | -$20.87M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | -$5.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | -$2.82M 10-Q · filed 2014-08-01 | -$8.77M derived: sum of 3 quarters · filed 2015-02-26 | -$13.28M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $2.71M 10-Q · filed 2014-05-08 | -$3.24M derived: sum of 2 quarters · filed 2015-02-26 | -$7.75M derived: sum of 3 quarters · filed 2015-02-26 | -$9.90M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | -$5.95M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$10.46M derived: sum of 2 quarters · filed 2015-02-26 | -$12.61M derived: sum of 3 quarters · filed 2015-02-26 | -$9.38M 10-K · filed 2015-02-26 |
| 2012-09-30 | -$4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$6.66M derived: sum of 2 quarters · filed 2013-11-07 | -$3.43M 10-Q · filed 2013-11-07 | -$8.63M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $1.07M 10-Q · filed 2013-08-09 | -$4.12M derived: sum of 3 quarters · filed 2014-02-27 | -$8.89M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $3.23M 10-Q · filed 2013-05-09 | -$1.97M derived: sum of 2 quarters · filed 2014-02-27 | -$6.74M derived: sum of 3 quarters · filed 2014-02-27 | -$11.73M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | -$5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$9.97M derived: sum of 2 quarters · filed 2014-02-27 | -$14.96M derived: sum of 3 quarters · filed 2014-02-27 | -$17.52M 10-K · filed 2014-02-27 |
| 2011-09-30 | -$4.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$9.77M derived: sum of 2 quarters · filed 2012-11-09 | -$12.32M 10-Q · filed 2012-11-09 | $23.76M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$4.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$7.55M 10-Q · filed 2012-08-09 | $28.53M derived: sum of 3 quarters · filed 2013-03-01 | $546.00K derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$2.56M 10-Q · filed 2012-05-04 | $33.53M derived: sum of 2 quarters · filed 2013-03-01 | $5.54M derived: sum of 3 quarters · filed 2013-03-01 | -$23.01M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $36.08M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $8.10M derived: sum of 2 quarters · filed 2013-03-01 | -$20.46M derived: sum of 3 quarters · filed 2013-03-01 | -$47.02M 10-K · filed 2013-03-01 |
| 2010-09-30 | -$27.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | -$56.54M derived: sum of 2 quarters · filed 2011-11-04 | -$83.11M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | -$28.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | -$55.12M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | -$26.57M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $126.80M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |